References
- Adkins, J. E., Boyer, E. W., & McCurdy, C. R. (2011). Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Current Topics in Medicinal Chemistry, 11(9), 1165–1175. https://doi.org/https://doi.org/10.2174/156802611795371305
- Ahmad, K., & Aziz, Z. (2012). Mitragyna speciosa use in the northern states of Malaysia: A cross-sectional study. Journal of Ethnopharmacology, 141(1), 446–450. https://doi.org/https://doi.org/10.1016/j.jep.2012.03.009
- Anwar, M., Law, R., & Schier, J. (2016). Notes from the field: Kratom (Mitragyna speciosa) exposures reported to poison centers — United States, 2010–2015. MMWR. Morbidity and Mortality Weekly Report, 65(29), 748–749. https://doi.org/https://doi.org/10.15585/mmwr.mm6529a4
- Assanangkornchai, S., Muekthong, A., Sam-angsri, N., & Pattanasattayawong, U. (2007). The use of mitragynine speciosa (“Krathom”), an addictive plant, in Thailand. Substance Use & Misuse, 42(14), 2145–2157. https://doi.org/https://doi.org/10.1080/10826080701205869
- Behnood-Rod, A., Chellian, R., Wilson, R., Hiranita, T., Sharma, A., Leon, F., McCurdy, C. R., McMahon, L. R., & Bruijnzeel, A. W. (2020). Evaluation of the rewarding effects of mitragynine and 7‐hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug and Alcohol Dependence, 215, 108235. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.108235
- Burkill, I. H. (1935). A dictionary of the economic products of the Malay Peninsula (Vol. 2). Crown Agents for the Colonies. pp. 1506–1508.
- Coe, M. A., Pillitteri, J. L., Sembower, M. A., Gerlach, K. K., & Henningfield, J. E. (2019). Kratom as a substitute for opioids: Results from an online survey. Drug and Alcohol Dependence, 202, 24–32. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2019.05.005
- Corkery, J. M., Streete, P., Claridge, H., Goodair, C., Papanti, D., Orsolini, L., Schifano, F., Sikka, K., Körber, S., & Hendricks, A. (2019). Characteristics of deaths associated with kratom use. Journal of Psychopharmacology, 33(9), 1102–1123. https://doi.org/https://doi.org/10.1177/0269881119862530
- Food and Drug Administration (FDA). (2018, April 5). Statement from FDA commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse. Silver Spring (MD). Retrieved August, 2020, from https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm595622.htm
- Garcia-Romeu, A., Cox, D. J., Smith, K. E., Dunn, K. E., & Griffiths, R. R. (2020). Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 208, 107849. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.107849
- Grundmann, O. (2017). Patterns of kratom use and health impact in the US—Results from an online survey. Drug and Alcohol Dependence, 176, 63–70. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2017.03.007
- Hassan, Z., Muzaimi, M., Navaratnam, V., Yusoff, N. H. M., Suhaimi, F. W., Vadivelu, R., Vicknasingam, B. K., Amato, D., Von Hörsten, S., Ismail, N. I. W., Jayabalan, N., Hazim, A. I., Mansor, S. M., & Müller, C. P. (2013). From kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience and Biobehavioral Reviews, 37(2), 138–151. https://doi.org/https://doi.org/10.1016/j.neubiorev.2012.11.012
- Hemby, S. E., McIntosh, S., Leon, F., Cutler, S. J., & McCurdy, C. R. (2018). Abuse liability and therapeutic potential of the mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology, 24(5), 874–885. https://doi.org/https://doi.org/10.1111/adb.12639
- Henningfield, J. E., Fant, R. V., & wang, D. W. (2018). The abuse potential of kratom according the 8 factor of the controlled substances act: Implications for regulation and research. Psychopharmacology, 235, 573–589.
- Henningfield, J. E., Fant, R. V., & Wang, D. W. (2017). The abuse potential of kratom according the 8 factors of the controlled substances act: Implications for regulation and research. Psychopharmacology, 235(2), 573–589. https://doi.org/https://doi.org/10.1007/s00213-017-4813-4
- Henningfield, J. E., Grundmann, O., Babin, J. K., Fant, R. V., Wang, D. W., & Cone, E. J. (2019). Risk of death associated with kratom use compared to opioids. Preventive Medicine, 128, 105851. https://doi.org/https://doi.org/10.1016/j.ypmed.2019.105851
- Jansen, K. L. R., & Prast, C. J. (1988). Ethnopharmacology of kratom and the Mitragyna alkaloids. Journal of Ethnopharmacology, 23(1), 115–119. https://doi.org/https://doi.org/10.1016/0378-8741(88)90121-3
- Kamble, S. H., Sharma, A., King, T. I., León, F., McCurdy, C. R., & Avery, B. A. (2019). Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of mitragyna speciosa (kratom). Xenobiotica, 49(11), 1279–1288. https://doi.org/https://doi.org/10.1080/00498254.2018.1552819
- Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., & Sames, D. (2016). Synthetic and receptor signaling explorations of themitragynaalkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. Journal of the American Chemical Society, 138(21), 6754–6764. https://doi.org/https://doi.org/10.1021/jacs.6b00360
- Lydecker, A. G., Sharma, A., McCurdy, C. R., Avery, B. A., Babu, K. M., & Boyer, E. W. (2016). Suspected adulteration of commercial Kratom products with 7-Hydroxymitragynine. Journal of Medical Toxicology, 12, 341–349.
- Marcan, A. (1929). Report of the Government Laboratory of Siam. Analyst, 54, 475–479.
- Post, S., Spiller, H. A., Chounthirath, T., & Smith, G. A. (2019). Kratom exposures reported to United States poison control centers: 2011–2017. Clinical Toxicology, 57(10), 847–854. https://doi.org/https://doi.org/10.1080/15563650.2019.1569236
- Prozialeck, W. C., Avery, B. A., Boyer, E. W., Grundmann, O., Henningfield, J. E., Kruegel, A. C., McMahon, L. R., McCurdy, C. R., Swogger, M. T., Veltri, C. A., & Singh, D. (2019). Kratom policy: The challenge of balancing therapeutic potential with public safety. International Journal of Drug Policy, 70, 70–77. https://doi.org/https://doi.org/10.1016/j.drugpo.2019.05.003
- Prozialeck, W. C., Jivan, J. K., & Andurkar, S. V. (2012). Pharmacology of kratom: An emerging botanical agent with stimulant, analgesic and opioid-like effects. The Journal of the American Osteopathic Association, 112(12), 792–799.
- Saingam, D., Assanangkornchai, S., Geater, A. F., & Balthip, Q. (2013). Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: A qualitative study. International Journal of Drug Policy, 24(4), 351–358. https://doi.org/https://doi.org/10.1016/j.drugpo.2012.09.004
- Saref, A., Suraya, S., Singh, D., Grundmann, O., Narayanan, S., Swogger, M. T., Prozialeck, W. C., Boyer, E., Chear, N. J. Y., & Balasingam, V. (2019). Self-reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects. Journal of Ethnopharmacology, 238, 111876. https://doi.org/https://doi.org/10.1016/j.jep.2019.111876
- Shellard, E. J. (1974). The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth. Bulletin on Narcotics, 26(2), 41–55.
- Singh, D., Grundmann, O., Murugaiyah, V., Rahim, A. B. M., Chawarski, M., & Balasingam, V. (2020b). Improved sexual functioning of long-term daily users of Mitragyna speciosa (Korth.). Journal of Herbal Medicine, 19, 100293.
- Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132–137. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2014.03.017
- Singh, D., Müller, C. P., Vicknasingam, B. K., & Mansor, S. M. (2015). Social functioning of kratom (Mitragyna speciosa) users in Malaysia. Journal of Psychoactive Drugs, 47(2), 125–131. https://doi.org/https://doi.org/10.1080/02791072.2015.1012610
- Singh, D., Murugaiyah, V., Hamid, S. B. S., Kasinather, V., Chan, M. S. A., Ho, E. T. W., Grundmann, O., Chear, N. J. Y., & Mansor, S. M. (2018c). Assessment of gonadotropins and testosterone hormone levels in regular Mitragyna speciosa (Korth.) users. Journal of Ethnopharmacology, 221, 30–36. https://doi.org/https://doi.org/10.1016/j.jep.2018.04.005
- Singh, D., Narayanan, S., Müller, C. P., Swogger, M. T., Chear, N. J. Y., Dzulkapli, E. B., Yusoff, N. S. M., Ramachandram, D. S., León, F., McCurdy, C. R., & Vicknasingam, B. (2019). Motives for using kratom (Mitragyna speciosa Korth.) among regular users in Malaysia. Journal of Ethnopharmacology, 233, 34–40. https://doi.org/https://doi.org/10.1016/j.jep.2018.12.038
- Singh, D., Narayanan, S., Müller, C. P., Swogger, M. T., Rahim, A. A., Abdullah, M. F. I. L., & Vicknasingam, B. K. (2018b). Severity of kratom (Mitragyna speciosa Korth.) psychological withdrawal symptoms. Journal of Psychoactive Drugs, 50(5), 445–450. https://doi.org/https://doi.org/10.1080/02791072.2018.1511879
- Singh, D., Narayanan, S., & Vicknasingam, B. (2016). Traditional and non-traditional uses of Mitragynine (kratom): A survey of the literature. Brain Research Bulletin, 126, 41–46. https://doi.org/https://doi.org/10.1016/j.brainresbull.2016.05.004
- Singh, D., Narayanan, S., Vicknasingam, B., Prozialeck, W. C., Ramanathan, S., Zainal, H., & Harun, S. N. (2018a). Severity of pain and sleep problems during kratom (Mitragyna speciosa Korth.) cessation among regular kratom users. Journal of Psychoactive Drugs, 50(3), 266–274. https://doi:https://doi.org/10.1080/02791072.2018.1443234
- Singh, D., Yeou Chear, N. J., Narayanan, S., Leon, F., Sharma, A., McCurdy, C. R., Avery, B. A., & Balasingam, V. (2020a). Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users. Journal of Ethnopharmacology, 249, 112462. https://doi.org/https://doi.org/10.1016/j.jep.2019.112462
- Smith, K. E., & Lawson, T. (2017). Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug and Alcohol Dependence, 180, 340–348. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2017.08.034
- Suwanlert, S. (1975). A study of kratom eaters in Thailand. Bulletin on Narcotics, 27(3), 21–27.
- Swogger, M. T., & Walsh, Z. (2018). Kratom use and mental health: A systematic review. Drug and Alcohol Dependence, 183, 134–140. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2017.10.012
- Takayama, H. (2004). Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chemical & Pharmaceutical Bulletin, 52(8), 916–928. https://doi.org/https://doi.org/10.1248/cpb.52.916
- Tanguay, P. (2011). Kratom in Thailand, decriminalisation and community control. Series on legislative reform of drug polices nr. 13. Transnational institute. International Drug Policy Consortium (IPDC).
- Thuan, L. C. (1957). Addiction to Mitragyna speciosa. In Proceedings of the Alumni Association (Vol. 10, pp. 322–324). University Malaya.
- Todd, D, A., Kellogg, J. J., Wallace, E. D., Khin, M., Flores-Bocanegra, L., Tanna, R. S., McIntosh, S., Raja, H. A., Graf, T. N., Hemby, S. E., Paine, M. F., Oberlies, N. H., & Cech, N. B. (2020). Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions. Scientific Report, 10(1), 19158. https://doi.org/https://doi.org/10.1038/s41598-020-76119-w
- Vicknasingam, B., Chooi, W. T., Rahim, A. A., Ramachandram, D., Singh, D., Ramanathan, S., Yusof, N., Zainal, H., Murugaiyah, V., Gueorguieva, R., Mansor, S. M., & Chawarski, M. C. (2020). Kratom and pain tolerance: A randomized, placebo-controlled, double-blind study. The Yale Journal of Biology and Medicine, 93(2), 229–238. PMC7309661.
- Vicknasingam, B., Narayanan, S., Beng, G. T., & Mansor, S. M. (2010). The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. International Journal of Drug Policy, 21(4), 283–288. https://doi.org/https://doi.org/10.1016/j.drugpo.2009.12.003
- Wilson, L. L., Harris, H. M., Eans, S. O., Brice-Tutt, A. C., Cirino, T. J., Stacy, H. M., Simons, C. A., Leớn, F., Sharma, A., Boyer, E. W., Avery, B. A., Mclaughin, J. P., & Mccurdy, C. R. (2020). Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug and Alcohol Dependence, 216, 108310. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2020.108310
- Yue, K., Kopajtic, T. A., & Katz, J. L. (2018). Abuse liability of mitragynine assessed with a self-administration procedure in rats. Psychopharmacology, 235(10), 2823–2829. https://doi.org/https://doi.org/10.1007/s00213-018-4974-9